Compare RDNT & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDNT | ACAD |
|---|---|---|
| Founded | 1985 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 3.8B |
| IPO Year | 1996 | 2000 |
| Metric | RDNT | ACAD |
|---|---|---|
| Price | $54.33 | $21.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 22 |
| Target Price | ★ $82.80 | $30.55 |
| AVG Volume (30 Days) | 787.6K | ★ 1.4M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | N/A | ★ 0.02 |
| Revenue | ★ $1,616,630,000.00 | $726,437,000.00 |
| Revenue This Year | $22.78 | $18.80 |
| Revenue Next Year | $10.70 | $11.70 |
| P/E Ratio | ★ N/A | $1,086.08 |
| Revenue Growth | 13.05 | ★ 40.45 |
| 52 Week Low | $50.79 | $19.69 |
| 52 Week High | $85.84 | $28.35 |
| Indicator | RDNT | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 47.25 | 49.69 |
| Support Level | $51.97 | $21.12 |
| Resistance Level | $55.99 | $22.03 |
| Average True Range (ATR) | 2.17 | 0.62 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 58.13 | 74.70 |
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostic.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.